Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
International Journal of Molecular Sciences|April 30, 2021
Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational ImplicationsKarim Rihawi, Angela Dalia Ricci, Alessandro Rizzo, et al.
Future Oncology (London, England)|February 3, 2022
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, et al.
Journal of Hepatocellular Carcinoma|September 13, 2023
Immune-Based Combination Therapies for Advanced Hepatocellular CarcinomaRiccardo Carloni, Simone Sabbioni, Alessandro Rizzo, et al.
Future Oncology (London, England)|April 21, 2021
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic reviewAlessandro Rizzo, Veronica Mollica, Filippo Gustavo Dall'Olio, et al.
Immunotherapy|March 23, 2023
Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?Angela Dalia Ricci, Rosalba D'Alessandro, Alessandro Rizzo, et al.
Cancers|November 7, 2020
Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and FailuresAlessandro Rizzo, Simona Tavolari, Angela Dalia Ricci, et al.
Expert Opinion on Biological Therapy|November 15, 2024
Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitorsCarmelo Laface, Emanuela Fina, Angela Dalia Ricci, et al.
In Vivo (Athens, Greece)|July 2, 2020
How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysisAlessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, et al.
Computer Methods and Programs in Biomedicine|July 4, 2025
Pharmacometric and Digital Twin modeling for adaptive scheduling of combination therapy in advanced gastric cancerMichela Prunella, Nicola Altini, Rosalba D'Alessandro, et al.
Expert Opinion on Drug Safety|November 25, 2022
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysisAlessandro Rizzo, Riccardo Carloni, Angela Dalia Ricci, et al.
Pageof 9